Lohith Gowda, MD, MRCP
Assistant Professor of Medicine (Hematology)DownloadHi-Res Photo
Cards
Appointments
Hematology
Primary
Additional Titles
Assistant Professor of Medicine (Hematology), Internal Medicine
About
Titles
Assistant Professor of Medicine (Hematology)
Assistant Professor of Medicine (Hematology), Internal Medicine
Biography
Curing hematologic cancers with precision medicine and minimal toxicity has been a multigeneration challenge and a highly prioritized work for our group at Yale. Through continual engagement with patients and their families, educational meetings and well informed decision making sessions, we help our patients navigate the field of transplantation and cellular therapy. Our multidisciplinary team while trying to harness the curative promise of cellular immunotherapy also has special focus to enhance its safety and provide long term supervision for cancer survivors. We strongly encourage our patients to learn the strengths and limitations of the existing standard of care, the knowledge of which could be applied to personalize treatment plans and foster research environment to advance the broader field.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Yale Cancer Center
- Yale Center for Immuno-Oncology
- Yale CTAP
- Yale Medicine
Education & Training
- Advanced Fellowship
- MD Anderson Cancer Center (2017)
- Advanced Fellowship
- NY Presbyterian Cornell/New York Blood Center (2016)
- Fellowship
- Albert Einstein College of Medicine (2014)
- Internship/Residency
- Drexel University College of Medicine (2011)
- General Medicine Trainee
- National Health Service UK (2008)
- MD
- Rajiv Gandhi University (2004)
Research
Overview
Targeted therapy; Transfusion Associated Immunomodulation, Immunotherapy, Cellular Therapy, Regenerative Medicine
Medical Subject Headings (MeSH)
Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Hematopoietic Stem Cell Transplantation; Immunotherapy; Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis
Research at a Glance
Yale Co-Authors
Frequent collaborators of Lohith Gowda's published research.
Publications Timeline
A big-picture view of Lohith Gowda's research output by year.
Research Interests
Research topics Lohith Gowda is interested in exploring.
Stuart Seropian, MD
Francine Foss, MD
Nikolai Podoltsev, MD, PhD
Noffar Bar, MD
Iris Isufi, MD
Jan Philipp Bewersdorf, MD
84Publications
744Citations
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Blood Transfusion
Primary Myelofibrosis
Leukemia
Multiple Myeloma
Publications
2024
Incidence of bacterial blood stream infections in patients with acute GVHD
Wallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem M, MacMillan M, Kitko C, Pidala J, Spellman S, Lee S, Alousi A. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplantation 2024, 1-6. PMID: 39420192, DOI: 10.1038/s41409-024-02426-9.Peer-Reviewed Original ResearchAltmetricConceptsBacterial bloodstream infectionsHematopoietic stem cell transplantationAcute GVHDNon-relapse mortalityGrade II-IV acute GVHDAllogeneic hematopoietic stem cell transplantationGrade III/IV acute GVHDBacterial blood stream infectionsAssociated with worse survivalStem cell transplantationBlood stream infectionsHigh-risk populationGVHD treatmentNeutrophil engraftmentBloodstream infectionsWorse survivalCell transplantationGI involvementOrgan involvementPost-transplantationPost-engraftmentRisk populationHigh riskPatientsGVHDP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchCitationsConceptsChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelA phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Al Malki M, Keyzner A, Suh H, Popat U, Gill S, Chen Y, Solh M, Gowda L, Buonomo E, Wang Y, Murray J, MacBeath G, Barton D, Chattopadhyay S, Reshef R. A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal Of Clinical Oncology 2024, 42: tps2678-tps2678. DOI: 10.1200/jco.2024.42.16_suppl.tps2678.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationMinimal residual diseaseEngineered T cell therapiesPatient hematopoietic cellsT-cell therapyMinor histocompatibility antigensHematopoietic cellsHLA-A*02:01Residual diseaseCell transplantationHematologic malignanciesPost-HCTT cellsHistocompatibility antigensTreatment armsCAR-T cell therapyAllogeneic hematopoietic cell transplantationHematopoietic cell transplant patientsPrevent disease relapseRelapse post-HCTDose-limiting toxicityDisease-free survivalEngineered T cellsHaploidentical donor transplantationSurrogate of efficacyReal-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, Perales M, Munoz J, Fingrut W, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza A, Abid M, Hong S, Majhail N, Kharfan-Dabaja M, Khurana A, Badar T, Lin Y, Bennani N, Herr M, Hu Z, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini M. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood 2024, 143: 2722-2734. PMID: 38635762, PMCID: PMC11251200, DOI: 10.1182/blood.2023023447.Peer-Reviewed Original ResearchCitationsAltmetricConceptsChimeric antigen receptorR/R LBCLNH-White patientsAxicabtagene ciloleucelZUMA-1ZUMA-7Autologous anti-CD19 chimeric antigen receptorCenter for International Blood and Marrow Transplant Research databaseAnti-CD19 chimeric antigen receptorHazard ratioOdds ratioLarge B-cell lymphomaProgression-free survivalT-cell therapyDuration of responseB-cell lymphomaCytokine release syndromeNH WhitesNH Black patientsAdjusted odds ratiosClinical trial settingClinical trial outcomesOverall survivalT cellsLBCLReal World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
Akhtar O, Hashmi H, Oloyede T, Brazauskas R, Bye M, Sidana S, Hansen D, Ahmed N, Ferreri C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Harrison M, Kitali A, Landau H, Mirza A, Patel J, Patwardhan P, Qazilbash M, Patel K, Nishihori T, Ganguly S, Pasquini M, Usmani S, Freeman C. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel. Transplantation And Cellular Therapy 2024, 30: s184-s185. DOI: 10.1016/j.jtct.2023.12.239.Peer-Reviewed Original ResearchCitationsConceptsCytokine-release syndromeProgression-free survivalTreatment-related mortalityClinically significant infectionsRelapse/refractory multiple myelomaOverall survivalIde-celProlonged cytopeniasMultiple myelomaBaseline characteristicsAnti-BCMA CAR-T cell therapyHematopoietic cell transplant-specific comorbidity indexFrail patientsComorbidity indexHigh-grade adverse eventsCAR-T cell therapyRates of overall responseNon-frail patientsRate of neurotoxicityClinically important subgroupsCharlson Comorbidity IndexAge cut-offAnti-BCMAHCT-CIComplete response
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchConceptsT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphomaCAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCitationsConceptsCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsReal World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCitationsConceptsCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response ratePost-transplantation cyclophosphamide is associated with increased bacterial infections
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, Cerny J, Gowda L, Hill J, Liu H, Munshi P, Nathan S, Seftel M, Wingard J, Chemaly R, Dandoy C, Perales M, Riches M, Papanicolaou G. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplantation 2023, 59: 76-84. PMID: 37903992, PMCID: PMC11164622, DOI: 10.1038/s41409-023-02131-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPost-transplant cyclophosphamideHematopoietic cell transplantationBacterial infectionsMost bacterial infectionsGVHD prophylaxisInfection cohortHost diseaseCalcineurin inhibitorsMyelodysplastic syndromeCell transplantationAcute leukemiaMore infectionsDay 180Greater incidencePatientsInfectionCohortProphylaxisCyclophosphamideTransplantationSyndromeGraftLeukemiaMortalityIncidence
Clinical Trials
Current Trials
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
HIC ID2000028478RoleSub InvestigatorPrimary Completion Date07/30/2023Recruiting ParticipantsA Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
HIC ID2000027145RoleSub InvestigatorPrimary Completion Date09/28/2028Recruiting ParticipantsManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
HIC ID2000025634RoleSub InvestigatorPrimary Completion Date07/06/2023Recruiting Participants
Academic Achievements & Community Involvement
activity American Society of Oncology
Professional OrganizationsMemberDetails2011 - Presentactivity American Society of Hematology
Professional OrganizationsMemberDetails2011 - Presentactivity Yale Stem Cell Transplant QI Committee
Professional OrganizationsMemberDetails2018 - Presentactivity YCC Data Safety Monitoring Committee
Professional OrganizationsMemberDetails2019 - Presentactivity American Society for Blood and Marrow Transplantation
Professional OrganizationsMemberDetails2017 - Present
Clinical Care
Overview
Lohith Gowda, MD, is a hematologist, which means he studies and treats blood-based diseases and cancers including leukemia and bone marrow failure.
Dr. Gowda’s team includes not just other doctors and scientists but patients and their families. The team meets often to help patients and families navigate the complexities of stem-cell transplant and cellular therapy, all of which are involved in the treatment of blood-based diseases. It is important for patients and families to fully understand options for care in order to make informed decisions, he says.
An active researcher, Dr. Gowda’s work examines the effectiveness of specific strategies for treating blood disorders, as well as their effects on patients’ well-being and long-term care. While transplantation may give patients a new lease on life, dedicated follow-up care for transplant recipients is vital, Dr. Gowda says.
Dr. Gowda is a member of the Royal College of Physicians and has received many awards, including the Young Investigator Award from the Academy of Clinical Laboratory Physicians and Scientists and the American Society of Hematology’s Abstract Achievement Award.
Clinical Specialties
Hematology
Fact Sheets
Cytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineAcute Myeloid Leukemia (AML)
Learn More on Yale MedicineCAR T-Cell Therapy
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- March 25, 2024
Yale’s Post ASH Review
- November 28, 2023
Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
- November 09, 2021
Discoveries & Impact, November 2021
- March 10, 2021
Discoveries & Impact (March 2021)
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.